May 28, 2019 10:39 AM EDT

‘I was shocked’: Controversy brews at Emory after prominent Chinese neuroscientists are ousted over disclosure issues

Amber Tong

It’s what Chinese scientists working in the US have been dreading since MD Anderson ousted three of its Asian faculty members following NIH-directed investigations …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

‘I was shocked’: Controversy brews at Emory after prominent Chinese neuroscientists are ousted over disclosure issues

Amber Tong

Sign up to read this article for free.

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Agilent reveals plans to remodel operations as annual revenue dips

‘I was shocked’: Con­tro­ver­sy brews at Emory af­ter promi­nent Chi­nese neu­ro­sci­en­tists are oust­ed over dis­clo­sure is­sues

Amber Tong

Sign up to read this article for free.

more like this

The Biden ad­min­is­tra­tion wants Medicare and Med­ic­aid to cov­er GLP-1s. Will the Trump White House al­low it?

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Ax­some moves to­ward NDA fil­ing for nar­colep­sy drug fol­low­ing pos­i­tive Phase 3 da­ta

Soleno’s rare pe­di­atric dis­ease drug faces PDU­FA de­lay by three months

Ag­i­lent re­veals plans to re­mod­el op­er­a­tions as an­nu­al rev­enue dips

‘I was shocked’: Controversy brews at Emory after prominent Chinese neuroscientists are ousted over disclosure issues

The Biden administration wants Medicare and Medicaid to cover GLP-1s. Will the Trump White House allow it?

Updated: Amgen obesity shot shows 20% weight loss, but dosing questions hang over readout

Sarepta licenses Arrowhead's RNA-based rare disease pipeline, promising big biobucks

Axsome moves toward NDA filing for narcolepsy drug following positive Phase 3 data

Soleno’s rare pediatric disease drug faces PDUFA delay by three months

Agilent reveals plans to remodel operations as annual revenue dips